DNLI — Denali Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.80bn
- $1.91bn
- 52
- 24
- 61
- 42
Annual income statement for Denali Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 336 | 48.7 | 108 | 331 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 273 | 344 | 449 | 527 | 487 |
| Operating Profit | 62.7 | -296 | -341 | -197 | -487 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 72 | -291 | -326 | -145 | -423 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 71.1 | -291 | -326 | -145 | -423 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 71.1 | -291 | -326 | -145 | -423 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 71.1 | -291 | -326 | -145 | -423 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.631 | -2.39 | -2.6 | -1.06 | -2.63 |